Modification of the ASTM Platelet and Leukocyte Assay: Use of an Alternative and Clinically Relevant Anticoagulant — An In-Vitro Hemocompatibility Assessment of Blood Contacting Medical Devices PUBLIC ACCESS

[+] Author Affiliations
Tim Schatz, Abby Beltrame, Sarah Howard, Mark Smith

American Preclinical Services, Minneapolis, MN

Paper No. DMD2017-3345, pp. V001T01A003; 2 pages
  • 2017 Design of Medical Devices Conference
  • 2017 Design of Medical Devices Conference
  • Minneapolis, Minnesota, USA, April 10–13, 2017
  • ISBN: 978-0-7918-4067-2
  • Copyright © 2017 by ASME


The purpose of this test method is to assist in the determination of the thrombogenic potential of medical materials exposed to human whole blood. By evaluating surface-induced activation, platelet adherence to a material, and platelet and leukocyte depletion from blood, a material’s potential for thrombus formation can be assessed. If a significant decrease in platelets and/or leukocytes is observed in whole blood when compared to a blank control, the tested material has the potential to induce an in-vivo thrombogenic response.

The present standard for the testing of platelet and leukocyte response to cardiovascular materials, ASTM F2888-13, Standard Test Method for Platelet Leukocyte Count - An In-Vitro Measure for Hemocompatibility Assessment of Cardiovascular Materials [1], mandates the use of several reference materials in the presence of blood anticoagulated with sodium citrate. This study was designed to address the relevance of the assay method when using a potent anticoagulant, 3.2% sodium citrate, to evaluate the thrombogenic potential of medical devices. Current studies on this question are under investigation at the FDA also with the intent of improving the standard methods for this assay by evaluating blood anticoagulated with 2–3 IU/mL of heparin [2]. For this study, the effects of several biomaterials were evaluated when exposed to blood anticoagulated with sodium citrate and, concurrently, an even lower dose of heparin at 1 IU/mL also used by our laboratory in a new circulating in vitro assay for thrombogenicity [3]. We believe this test method allows for a sensitive assay that can more accurately predict potential thrombogenic outcomes of cardiovascular materials, while maintaining appropriate responses in both positive and negative control materials.

Copyright © 2017 by ASME
This article is only available in the PDF format.



Interactive Graphics


Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging and repositioning the boxes below.

Related eBook Content
Topic Collections

Sorry! You do not have access to this content. For assistance or to subscribe, please contact us:

  • TELEPHONE: 1-800-843-2763 (Toll-free in the USA)
  • EMAIL: asmedigitalcollection@asme.org
Sign In